Royal Bank of Canada lifts target for Pacira BioSciences stock to USD 36.50

Published on 10/15/2026 at 19:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue in the second quarter was USD 192.40 million, up 6.20 percent. Pacira BioSciences stock costs EUR 32.50 on October 15, 2026.

Target actions and earnings

Royal Bank of Canada raised its Pacira target from USD 25.00 to USD 36.50 on October 9, 2026.
Revenue in the second quarter was USD 192.40 million, up 6.20 percent year over year.
Pacira BioSciences stock costs EUR 32.50 at Lang & Schwarz on October 15, 2026 at 6:59 p.m. CEST.
Pacira had a USD 1.4 billion market capitalization and a 103.49 price-to-earnings ratio.

PCRX, US6951271005, Illustration mit AI erstellt.

Royal Bank of Canada raised its Pacira BioSciences price target from USD 25.00 to USD 36.50 on October 9, 2026, while keeping a sector perform rating, according to MarketBeat. That target sits USD 0.15 above the latest primary-market price of USD 36.35. Pacira BioSciences stock was trading at EUR 32.50 at Lang & Schwarz on October 15, 2026 at 6:59 p.m. CEST.

Second-quarter revenue grew 6.20 percent

Pacira reported USD 192.40 million in revenue for the second quarter of 2026, a 6.20 percent increase from the year-earlier quarter. The company posted net income attributable to common shareholders of USD 4.65 million, or USD 0.12 in diluted earnings per share, for the same period. MarketBeat reported revenue of USD 192.40 million against consensus of USD 191.06 million and adjusted earnings per share of USD 0.73 against USD 0.65 expected.

Stock stays near its yearly high

The primary Nasdaq quote was USD 36.35 at 1:01 p.m. ET on October 15, 2026. Pacira's 52-week range was USD 18.80 to USD 36.66, placing the latest price USD 0.31 below the high. Trading volume was 762,954 shares against an average of 1,177,937 shares in the latest quote.

Valuation and target distance

Pacira had a USD 1.4 billion market capitalization and a 103.49 price-to-earnings ratio. The USD 36.50 Royal Bank of Canada target is 0.41 percent above the USD 36.35 Nasdaq price, while the broader consensus target cited by MarketBeat was USD 32.72 from nine analysts.

Comparison with peers

Pacira BioSciences (Nasdaq, USD): P/E 103.49, market capitalization USD 1.4 billion.
Bristol-Myers Squibb (NYSE, USD): plus 3.10 percent, P/E 13.47, market capitalization USD 124.9 billion.
Vertex Pharmaceuticals (Nasdaq, USD): plus 2.30 percent, P/E 29.66, market capitalization USD 129.3 billion.

Trading snapshot

Pacira combines second-quarter revenue growth with a share price close to its 52-week high and an analyst target near the Nasdaq quote. The next calendar date is not included because no future reporting date is stated in the cited materials.

Pacira BioSciences stock was trading at EUR 32.50 at Lang & Schwarz on October 15, 2026 at 6:59 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Pacira BioSciences stock.